About the Study
There are few treatments approved for the acute treatment of migraines in adolescents and only one treatment approved for children ages 6 – 11 years old. Rochester Clinical Research is conducting a research study to test the safety, effectiveness, and tolerability of a migraine medication called Lasmiditan for migraines in children. The study drug works by blocking the pain pathway from the nerves in your head.
The study will last approximately 4 months with 3 visits to our office. Compensation is available for time and travel up to $225, for those who qualify. Study related care is available to participants at no cost and health insurance is not required nor needed.
- Between the ages of 6 – 17 years old
- Patient has a history of 2-8 migraines per month, in the last 3 months prior to screening
- Patient must be able to swallow a tablet medication.
- Please note, other conditions may apply.